PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pharmacogenet Genomics. Author manuscript; available in PMC 2010 December 8.
Published in final edited form as:
PMCID: PMC2998989
NIHMSID: NIHMS202809

Taxane Pathway

Overview

Taxanes, such as paclitaxel and docetaxel, are widely prescribed chemotherapeutic drugs [1-3]. They have been used to treat many forms of cancer including breast, ovarian and lung cancers [1]. Paclitaxel was isolated from the Pacific yew in 1971 and docetaxel, a second generation taxane, is a semi-synthetic taxane analogue from the European yew identified approximately 20 years later [2]. The pathway above depicts the known candidate pharmacogenes involved in the pharmacokinetics and pharmacodynamics of taxanes.

Microtubules display a form of non-equilibrium dynamics referred to as dynamic instability that is essential to cell division [3]. Dynamic instability is regulated by microtubule-associated proteins (MAPs) including MAPT, MAP2 and MAP4 [3]. In an un-phosphorylated state, the MAP proteins bind and stabilize microtubules, leading to cell death [3].

Microtubules are composed of α–tubulin and β–tubulin heterodimers [1]. Taxanes block cell division by binding to β–tubulin, stabilizing the microtubules, leading to cell death [1, 4]. A 3.5A structure of bovine β–tubulin, with bound paclitaxel, can be found in the Protein Data Bank [5], entry 1JFF [6]. In addition, in vitro studies have shown taxanes to induce BCL2 phosphorylation and apoptosis, with docetaxel doing so at much lower concentrations than paclitaxel [7, 8].

While paclitaxel and docetaxel share many common structural features, their pharmacology and pharmacokinetics differ somewhat. Consequently, in some patients, solid tumors with resistance to paclitaxel have been shown to be sensitive to docetaxel [9, 10].

The pharmacokinetics of taxanes are complex and are complicated by their different formulations [11]. Both taxanes are primarily metabolized in the liver and their primary route of elimination of the parent drug and hydroxylated metabolite is through biliary excretion via feces [2]. Early work found that docetaxel had linear pharmacokinetics but paclitaxel did not [2, 12]. However, the two taxanes have different formulations: paclitaxel is dissolved in Cremaphor EL (CrEL, poly-oxyethyleneglycol triricinoleate 35)/ethanol (1:1) where as docetaxel is dissolved in polysorbate 80 (Tween 80) [13]. Tween 80 was found to alter the fraction of unbound docetaxel in patients [13] and another study found that in the absence of CrEL, the bioavailability of intraperitoneal paclitaxel was significantly increased [14]. Various other studies have shown that CrEL alters the pharmacokinetic behavior of many drugs, including paclitaxel [13, 15]. Finally, a small study of the recently available, 130-nm albumin-bound (nab) particle formulation of paclitaxel, devoid of solvents, found that the disposition of paclitaxel is subject to considerable variability, depending upon the formulation used [16].

Both paclitaxel [17, 18] and docetaxel [17, 19-21] are metabolized by CYP3A4. Paclitaxel is also metabolized by CYP2C8 [22, 23], while docetaxel is also metabolized by CYP3A5 [21]. In an in vitro study, a highly significant induction level of PXR (gene NR1I2) -mediated CYP3A4 expression was observed for paclitaxel, whereas docetaxel only moderately increased CYP3A4 expression [24]. In another study, paclitaxel activated PXR, but docetaxel did not [25]. Paclitaxel was also found to activate PXR and enhances P-glycoprotein (ABCB1) mediated drug clearance [25] and ABCB1 expression [26] as well as CYP2C8 expression [27].

Both paclitaxel and docetaxel are substrates for the ATP binding cassette multidrug transporters ABCB1, ABCG2, ABCC1 and ABCC2 [28-34]. OATP1B3 (SLCO1B3) was identified as the most efficient influx transporter for docetaxel [35] and identified as a key regulator of paclitaxel hepatic uptake [36, 37]. OAT2 (SLC22A7) was found to transport paclitaxel in in vitro experiments [38].

Taxane resistance is frequent [3, 39, 40]. Possible mechanisms for such resistance are many, but definitive data for the causes of resistance remain unclear. There are several genes that encode α– and β–tubulins and different tubulins also arise from different post-translational modifications [41]. Such structural diversity makes comparative analysis between tubulins in drug-sensitive and drug-resistant cell lines difficult [42]. Exposure to taxane creates somatic mutations in tubulins, but the relationship of somatic mutations to resistance remains unclear, even for those mutations near the taxane binding site [43]. While an early study found a relationship between mutations in the tubulin-encoding TUBB gene and paclitaxel treatment response and clinical outcome (in tissue samples of patients with advanced non-small-cell lung cancer) [44], numerous other genetic and mutational analysis of the gene in cell lines and patients with lung cancer, breast cancer and ovarian cancer did not find such a relationship [45-54], suggesting that mutations in TUBB do not play a role in taxane resistance. Genetic and mutational analysis of the TUBB gene has been complicated due to the presence of several pseudogenes with high homology to the wild type gene [52, 53]. Increased expression level of tubulins as a mechanism for resistance remains contradictory, although there is growing evidence that this does lead to resistance for particular tubulins [43]. Recently, high levels of chromosomal instability, and the genes involved in this instability, have been found to be related to taxane resistance [55]

Pharmacogenetics

The impact of genetic variants on taxane response is unclear: several studies did not find relationships between polymorphisms of genes in the taxane pathway, while others did. For example, in a large study (n=914) of ovarian cancer patients from the Scottish Randomized Trial in Ovarian Cancer (SCOTROC) phase III trial who were treated at presentation with carboplatin and taxane regimens, no association between polymorphisms of genes in the pathway and taxane response was found [56]. This study assessed polymorphisms in 11 genes (ABCB1, ABCC1, ABCC2, ABCG2, CDKN1A, CYP1B1, CYP2C8, CYP3A4, CYP3A5, MAPT, and TP53) and found no reproducible significant associations between genotype and outcome or toxicity [56]. Similarly, in two other studies, no significant association was seen between ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and paclitaxel clearance or ABCB1, CYP2C8, CYP3A4 and CYP3A5 and paclitaxel clearance [57, 58].

In contrast, other studies of genes in the taxane pathway did find associations between polymorphisms of the genes and either patient survival or drug response. With respect to survival, one study found rs1056836, CYP1B1*3 (4326 C>G; L432V) allele, was significantly associated with progression-free survival, independent of paclitaxel clearance [57]. The same SNP was also associated with survival in patients receiving docetaxel [59]. In a recent study of patients with metastatic breast cancer, the synonymous variant rs1045642 (ABCB1: 3435 C>T), showed a significantly lower disease control rate and lower overall survival rate than the CC genotype for the variant allele [60].

Other small studies have found associations between variants of ABCB1 and taxane pharmacokinetics. One small study of Japanese patients found associations with ABCB1 polymorphisms, including paclitaxel pharmacokinetics and ABCB1 variants [61]. Another small study of Japanese patients found that those with the ABCB1:3435C>T (rs1045642) allele had a significantly higher AUC of a paclitaxel metabolite when compared to those possessing the 3435C allele[62]. Other studies associated ABCB1: 2677G>T/A with response to paclitaxel [63], response to taxane- and platinum-based chemotherapy [64] and gastrointestinal toxicity [64]. A combination of ABCB1:2677G>T/A and ABCB1:3435C>T (rs1045642) genotypes have been associated with neutropenia from paclitaxel therapy [65]. A recent small study of Caucasian patients found that the interindividual variability in paclitaxel clearance to be related to variants in ABCB1; in particular, patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants [66].

That same study found variability in paclitaxel clearance to also be related to CYP2C8 genotype; the CYP2C8*3 had lower clearance of paclitaxel [66].. Another recent small study of docetaxel clearance found greater clearance with patients with the CYP3A4*1B and CYP3A5*1A alleles [35]. Most of these findings remain to be validated.

Fig.1
Representation of known candidate genes involved in the pharmacokinetics and pharmacodynamics of taxanes.

References

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–265. [PubMed]
2. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 2:3–8. [PubMed]
3. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132. [PubMed]
4. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. Taxanes: a new class of antitumor agents. Cancer Invest. 1995;13:381–404. [PubMed]
5. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–242. [PMC free article] [PubMed]
6. Lowe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol. 2001;313:1045–1057. [PubMed]
7. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–233. [PubMed]
8. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995;92:4507–4511. [PubMed]
9. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16:3362–3368. [PubMed]
10. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol. 2000;18:2733–2739. [PubMed]
11. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19:125–141. [PubMed]
12. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180–190. [PubMed]
13. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–685. [PubMed]
14. Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002;8:1237–1241. [PubMed]
15. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–1598. [PubMed]
16. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14:4200–4205. [PMC free article] [PubMed]
17. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos. 1998;26:229–233. [PubMed]
18. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther. 1995;275:566–575. [PubMed]
19. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther. 2004;75:448–454. [PubMed]
20. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99–114. [PubMed]
21. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998;8:391–401. [PubMed]
22. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597–607. [PubMed]
23. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos. 2002;30:438–445. [PubMed]
24. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009;64:35–43. [PubMed]
25. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584–590. [PubMed]
26. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 2005;19:1170–1180. [PubMed]
27. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol. 2005;68:747–757. [PubMed]
28. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res. 2003;20:24–30. [PubMed]
29. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000;60:5761–5766. [PubMed]
30. Su GM, Davey MW, Davey RA. Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer. 1998;76:702–708. [PubMed]
31. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002;110:1309–1318. [PMC free article] [PubMed]
32. Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003;2:1195–1205. [PubMed]
33. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006;12:6125–6132. [PubMed]
34. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116:824–829. [PubMed]
35. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85:155–163. [PubMed]
36. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005;4:815–818. [PubMed]
37. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther. 2007;81:76–82. [PubMed]
38. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]) J Pharm Pharmacol. 2005;57:573–578. [PubMed]
39. Materna V, Surowiak P, Kaplenko I, Spaczynski M, Duan Z, Zabel M, Dietel M, Lage H. Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch. 2007;450:187–194. [PubMed]
40. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005;5:65–71. [PubMed]
41. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol. 1998;178:207–275. [PubMed]
42. Verdier-Pinard P, Wang F, Burd B, Angeletti RH, Horwitz SB, Orr GA. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry. 2003;42:12019–12027. [PubMed]
43. Huzil JT, Chen K, Kurgan L, Tuszynski JA. The Roles of beta-Tubulin Mutations and Isotype Expression in Acquired Drug Resistance. Cancer Inform. 2007;3:159–181. [PMC free article] [PubMed]
44. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17:1786–1793. [PubMed]
45. Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst. 2001;93:1886–1888. [PubMed]
46. Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M, Kohno S, Fukuoka M, Nakagawa K. Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer. 2002;35:11–16. [PubMed]
47. Sale S, Oefner PJ, Sikic BI. Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst. 2002;94:776–777. author reply 777. [PubMed]
48. Kohonen-Corish MR, Qin H, Daniel JJ, Cooper WA, Rivory L, McCaughan B, Millward MJ, Trent RJ. Lack of beta-tubulin gene mutations in early stage lung cancer. Int J Cancer. 2002;101:398–399. [PubMed]
49. Maeno K, Ito K, Hama Y, Shingu K, Kimura M, Sano M, Nakagomi H, Tsuchiya S, Fujimori M. Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett. 2003;198:89–97. [PubMed]
50. Mesquita B, Veiga I, Pereira D, Tavares A, Pinto IM, Pinto C, Teixeira MR, Castedo S. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer. 2005;5:101. [PMC free article] [PubMed]
51. Green H, Rosenberg P, Soderkvist P, Horvath G, Peterson C. beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. Cancer Lett. 2006;236:148–154. [PubMed]
52. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Tamaki Y, Monden M, Noguchi S. Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer. 2002;101:46–51. [PubMed]
53. de Castro J, Belda-Iniesta C, Cejas P, Casado E, Fresno Vara JA, Hardisson D, Sanchez JJ, Feliu J, Ordonez A, Nistal M, Gonzalez-Baron M. New insights in beta-tubulin sequence analysis in non-small cell lung cancer. Lung Cancer. 2003;41:41–48. [PubMed]
54. Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res. 2003;23:681–686. [PubMed]
55. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A. 2009;106:8671–8676. [PubMed]
56. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007;25:4528–4535. [PubMed]
57. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007;7:362–365. [PubMed]
58. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005;11:8097–8104. [PubMed]
59. Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther. 2008;7:19–26. [PubMed]
60. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009;20:272–277. [PubMed]
61. Yamaguchi H, Hishinuma T, Endo N, Tsukamoto H, Kishikawa Y, Sato M, Murai Y, Hiratsuka M, Ito K, Okamura C, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer. 2006;16:979–985. [PubMed]
62. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, Tanaka M, Inoue M, Yokoi T. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol. 2005;45:674–682. [PubMed]
63. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006;12:854–859. [PubMed]
64. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113:264–269. [PubMed]
65. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006;42:2893–2896. [PMC free article] [PubMed]
66. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009;104:130–137. [PubMed]